MA28748B1 - Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques - Google Patents

Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques

Info

Publication number
MA28748B1
MA28748B1 MA29627A MA29627A MA28748B1 MA 28748 B1 MA28748 B1 MA 28748B1 MA 29627 A MA29627 A MA 29627A MA 29627 A MA29627 A MA 29627A MA 28748 B1 MA28748 B1 MA 28748B1
Authority
MA
Morocco
Prior art keywords
self
lipid excipients
galenic
applications
emulsifiable
Prior art date
Application number
MA29627A
Other languages
English (en)
Inventor
Jean Pachot
Chicq Serge Segot
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA28748B1 publication Critical patent/MA28748B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention a pour objet de nouvelles formulations galéniques permettant d'améliorer l'absorption intestinale de principes actifs administrés par voie orale, leur procédé de préparation ainsi que l'application d'excipients lipidiques associés à un ou des tensioactifs et un ou des co-tensioactifs pour inhiber les pompes à efflux.
MA29627A 2004-07-27 2007-01-23 Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques MA28748B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408269A FR2873585B1 (fr) 2004-07-27 2004-07-27 Nouvelles formulations galeniques de principes actifs

Publications (1)

Publication Number Publication Date
MA28748B1 true MA28748B1 (fr) 2007-07-02

Family

ID=34951660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29627A MA28748B1 (fr) 2004-07-27 2007-01-23 Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques

Country Status (18)

Country Link
US (2) US20080193519A1 (fr)
EP (1) EP1771154A1 (fr)
JP (1) JP2008508191A (fr)
KR (1) KR20070046819A (fr)
CN (1) CN101001608A (fr)
AU (1) AU2005273839A1 (fr)
BR (1) BRPI0513622A (fr)
CA (1) CA2579449A1 (fr)
FR (1) FR2873585B1 (fr)
IL (1) IL180714A0 (fr)
MA (1) MA28748B1 (fr)
MX (1) MX2007001141A (fr)
NO (1) NO20070354L (fr)
NZ (1) NZ552715A (fr)
RU (1) RU2381789C2 (fr)
TW (1) TW200616640A (fr)
WO (1) WO2006018501A1 (fr)
ZA (1) ZA200700553B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1867323A1 (fr) * 2006-06-13 2007-12-19 Farmatron Ltd. Formulations pharmaceutiques avec pénétration améliorée à travers des barrières biologiques
MX2010001730A (es) * 2007-08-21 2010-03-10 Basilea Pharmaceutica Ag Composicion antimicotica.
JP5951489B2 (ja) 2009-10-16 2016-07-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組成物
JP2013209294A (ja) * 2010-07-30 2013-10-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 液状医薬組成物
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (fr) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone stéroïde
WO2020123551A1 (fr) * 2018-12-10 2020-06-18 Halo Science LLC Formulations stables d'anesthésiques et formes galéniques associées
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
CN114246827B (zh) * 2022-01-04 2023-04-11 中山大学 一种鱼油微乳制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916901D0 (en) * 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
FR2710535B1 (fr) * 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
EP0933367A1 (fr) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Dérivés d'acylguanidine comme inhibiteurs de résorbtion osseuse et comme antagonistes de récepteur vitronectine
WO1999037621A1 (fr) * 1998-01-23 1999-07-29 Aventis Pharma Deutschland Gmbh Nouveaux derives de sulfamide comme inhibiteurs de la resorption osseuse et comme inhibiteurs de l'adherence cellulaire
AU756752B2 (en) * 1998-04-01 2003-01-23 Skyepharma Canada Inc. Anticancer compositions
CA2302735A1 (fr) * 1998-07-14 2000-01-27 Em Industries, Inc. Systemes d'apport de medicaments par microdispersion
GB0003685D0 (en) * 2000-02-17 2000-04-05 Univ Cardiff Sensitisation of cellular material
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
JP4464814B2 (ja) * 2002-05-14 2010-05-19 アバーント・ファーマシューティカルズ・（インディア）・リミテッド アントラニル酸誘導体の水和物の製造方法

Also Published As

Publication number Publication date
ZA200700553B (en) 2008-05-28
CA2579449A1 (fr) 2006-02-23
NZ552715A (en) 2010-12-24
AU2005273839A1 (en) 2006-02-23
NO20070354L (no) 2007-04-17
RU2007107199A (ru) 2008-09-10
WO2006018501A1 (fr) 2006-02-23
WO2006018501A8 (fr) 2007-03-01
RU2381789C2 (ru) 2010-02-20
EP1771154A1 (fr) 2007-04-11
JP2008508191A (ja) 2008-03-21
US20110104268A1 (en) 2011-05-05
FR2873585A1 (fr) 2006-02-03
CN101001608A (zh) 2007-07-18
KR20070046819A (ko) 2007-05-03
IL180714A0 (en) 2007-06-03
US20080193519A1 (en) 2008-08-14
BRPI0513622A (pt) 2008-05-13
FR2873585B1 (fr) 2006-11-17
MX2007001141A (es) 2007-04-19
TW200616640A (en) 2006-06-01

Similar Documents

Publication Publication Date Title
MA28748B1 (fr) Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
BRPI0516132A (pt) compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
MA31849B1 (fr) Nouveaux dérivés de pyrimidine
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
MA29856B1 (fr) Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
EA200701113A1 (ru) Макролиды
WO2006021160A8 (fr) Système de relargage de médicament auto-émulsifiant à base de butylbenzènephtaléine, méthode de préparation et applications d’un tel système
ATE365538T1 (de) O/w emulsion
EA200870545A1 (ru) Новые гетероциклические соединения
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
MA29723B1 (fr) Composes
NO20070580L (no) Behandling av cancer.
TNSN06440A1 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer
DE60219005D1 (de) Feste pharmazeutische formulierung enthaltend modafinil
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
BRPI0514724A (pt) inibidores da enzima hiv integrase
DE60115402D1 (de) Neues selbstemulgierendes arzneistoffverabreichungssystem
Palit et al. Oral therapy with amlodipine and lacidipine, 1, 4-dihydropyridine derivatives showing activity against experimental visceral leishmaniasis
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl